Biospecimen Core

生物样本核心

• 批准号: 10333518
• 负责人: Olca Basturk
• 金额: $ 12.35万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10333518
• 关键词: Adjuvant; American; Basic Science; Biological Assay; Biological Specimen Banks; Blood; CLIA certified; Cancer Patient; Cell Line; Cell Survival; Clinical; Collaborations; Collection; Consent; Databases; Diagnosis; Documentation; Effectiveness; Enrollment; Ensure; Evaluation; Excision; Formalin; Freezing; Generations; Genomics; Goals; Heterogeneity; Human; Immunohistochemistry; Infrastructure; Laboratories; Malignant Neoplasms; Malignant neoplasm of pancreas; Measures; Memorial Sloan-Kettering Cancer Center; Microdissection; Microscopic; Molecular Analysis; Morphology; Mutation; Neoadjuvant Therapy; Normal tissue morphology; Organoids; Pancreas; Pancreatic Ductal Adenocarcinoma; Paraffin Embedding; Pathologic; Pathologist; Pathology; Patient-Focused Outcomes; Patients; Plasma; Play; Protocols documentation; Quality Control; Randomized Controlled Trials; Recording of previous events; Reproducibility; Research; Research Personnel; Research Project Grants; Resistance; Resources; Role; Sampling; Services; Specimen; Standardization; System; Techniques; Therapeutic Human Experimentation; Tissue Microarray; Tissue Sample; Tissues; Translational Research; Treatment Protocols; Tumor Tissue; Work; adjudicate; anticancer research; biobank; cancer cell; college; cost effective; data quality; design; diagnostic value; exome sequencing; follow-up; human tissue; laser capture microdissection; molecular diagnostics; molecular oncology; mouse model; pancreatic ductal adenocarcinoma model; pancreatic neoplasm; peripheral blood; programs; prospective; quality assurance; relational database; response; single cell sequencing; treatment response; tumor

PROJECT SUMMARY – BIOSPECIMEN CORE The Biospecimen Core is designed to provide expert support to the translational research efforts of the Memorial Sloan Kettering Cancer Center (MSK) Pancreas SPORE. The Core will leverage and extend the very active tissue banking program and molecular diagnostics capabilities of the MSK Precision Pathology Biobanking Core (PPBC), which anchors 4 other MSK SPOREs and the MSK Center for Pancreatic Cancer Research. The SPORE Biospecimen Core will play an essential role in collection, annotation, storage, distribution, and tracking of pancreatic cancer biospecimens (tissue and blood) from patients enrolled in institutional biospecimen banking protocols and therapeutic research protocols. Detailed biospecimen annotation, including documentation of preanalytic processing variables, pathology findings, and patient clinical history information will be recorded in robust relational databases. We will conduct rigorous data quality assurance and quality control measures, and standardized longitudinal follow-up of all consented patients with materials in the pancreatic cancer biospecimen repository. The Core will also provide SPORE investigators with expert histopathological evaluation of tumor samples, as well as assistance in performing and interpreting immunohistochemical assays, selecting tissue for microdissection for downstream analysis, constructing tissue microarrays, and facilitating patient-derived organoid creation. The specific aims of the core are to (1) maintain and expand the collection, annotation, and storage of biospecimens for pancreatic cancer research, (2) perform systematic pathologic evaluation of all relevant ductal pancreatic adenocarcinoma samples and to prepare appropriate biospecimens for use by SPORE investigators, and (3) provide systematic microscopic assessment of response to therapy. Given the significant heterogeneity of pancreatic cancers, each of these aims requires expertise beyond what existing resources can provide, underscoring the need for this Core. All of the research projects will rely extensively on the Biospecimen Core to achieve their translational research objectives.

项目摘要 – 生物样本核心 生物样本核心旨在为转化研究工作提供专家支持 纪念斯隆凯特琳癌症中心 (MSK) 胰腺 SPORE 核心将利用并扩展这一功能。 MSK Precision Pathology 的主动组织库计划和分子诊断功能 生物样本库核心 (PPBC)，支持其他 4 个 MSK SPORE 和 MSK 胰腺癌中心 SPORE 生物样本核心将在收集、注释、存储、 纳入患者的胰腺癌生物样本（组织和血液）的分布和跟踪 机构生物样本库协议和详细的生物样本治疗研究协议。 注释，包括分析前处理变量、病理结果和患者临床的记录 历史信息将记录在强大的关系数据库中，我们将进行严格的数据质量检查。 保证和质量控制措施，以及对所有同意的患者进行标准化纵向随访 The Core 还将为 SPORE 研究人员提供胰腺癌生物样本库中的材料。 专家对肿瘤样本进行组织病理学评估，并协助执行和解释 免疫组织化学测定、选择用于下游分析的显微切割组织、构建组织 微阵列，并促进源自患者的类器官的创建，核心的具体目标是（1）维持。 并扩大用于胰腺癌研究的生物样本的收集、注释和存储，(2) 执行 对所有相关的胰腺导管腺癌样本进行系统病理学评估并准备 供 SPORE 研究人员使用的适当生物样本，以及 (3) 提供系统显微镜 鉴于胰腺癌的显着异质性，对治疗的反应进行评估。 目标需要超出现有资源所能提供的专业知识，强调了对这一核心的需求。 的研究项目将主要依靠生物样本核心来实现其转化研究 目标。